Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of niraparib plus dostarlimab in PD-L1 positive pleural mesothelioma or non-small cell lung cancer with HRR gene mutations
2024-515555-38-01Phase 2Authorised
- Sponsor
- University of Turin
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab and niraparib in pleural mesothelioma and non-small cell lung cancer (NSCLC), sponsored by University of Turin. Primary endpoint: progression free survival. Planned start Dec 2024; status: authorised.
02
Drugs
dostarlimabniraparib
03
Conditions
pleural mesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515555-38-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515555-38-01.